Treatment for diffuse benign breast diseases
Timely treatment for benign breast dysplasia (BBD) should be considered as a cancer prevention measure. Objective: To evaluate the efficiency of BBD treatment with the non-hormonal herbal remedy indole carbinol (Indinol Forto). Materials and methods: A total of 150 women aged 30–49 years were comprehensively examined using breast examination and sonography and mammography. The patients were divided into 2 groups. A study group consisted of 75 women with BBD: with benign changes (according to Breast Imaging-Reporting and Data System 2 (BI-RADS 2), manifested as small cysts (up to 10 mm), as well as duct ectasias concurrent with cyclical mastalgias. All the patients were prescribed combination treatment, including concomitant measures. The study group women took indole carbinol-based drugs to treat BBD. A comparison group included 75 women with benign changes (BI-RADS 2), who refused drug treatment for various reasons. Results: Minor mammographic density was noted in 69.3% of the study group patients and in 34.7% of the comparison group (p<0.001); moderate one was seen in 26.6 and 42.7%, respectively (p=0.040). Severe mammographic density was determined in 2.7% of cases in the study group and in 13.3% of those in the comparison group (p=0.017); pronounced one was observed in 1.3% and 9.3% in these groups, respectively (p=0.030). Conclusion: Indinol Forto is shown to be highly effective in treating BBD. Combined with concomitant measures, 6-month therapy with this drug substantially reduces mammographic density. The drug is well tolerated and has no adverse side effects. It can be recommended for widespread use as a first-line drug in women with increased breast density. Authors’ contributions: Kravchenko E.N. – the concept and design of the investigation, analysis of the findings, writing the text, approval of the final version of the article; Naboka M.V. – material collection and processing, analysis and interpretation of these treatment results, writing the text. Conflicts of interest: The authors declare that there are no conflicts of interest. Funding: The investigation has not been sponsored. Patient Consent for Publication: All patients provided informed consent for the publication of their data. Authors' Data Sharing Statement: The data supporting the findings of this study are available on request from the corresponding author after approval from the principal investigator. For citation: Kravchenko E.N., Naboka M.V. Treatment for diffuse benign breast diseases. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2023; (2): 140-145 (in Russian) https://dx.doi.org/10.18565/aig.2023.25Kravchenko E.N., Naboka M.V.
Keywords
benign breast dysplasia
mastodynia
mastalgia
mastopathy
indinol carbinol
Indinol Forto
References
- Каприн А.Д., Рожкова Н.И., ред. Маммология. Национальное руководство. М.: ГЭОТАР-Медиа; 2016. [Kaprin A.D., Rozhkova N.I., eds. Mammology: a national guide. Moscow: GEOTAR-Media; 2016. (in Russian)].
- Рожкова Н.И., Бурдина И.И., Запирова С.Б., Мазо М.Л., Прокопенко С.П., Якобс О.Э. Своевременное лечение диффузных гиперплазий – профилактика рака молочной железы. Онкогинекология. 2016; 1: 4-11. [Rozhkova N.I., Burdina I.I., Zapirova S.B., Mazo M.L., Prokopenko S.P., Yakobs O.E. Early treatment of diffuse hyperplasia – is a prevention of breast cancer. Oncogynecology. 2016; (1): 4-11. (in Russian)].
- Руженков В.А., Шуличенко Е.А. Психические расстройства у женщин с доброкачественной дислазией молочной железы. Современные проблемы науки и образования. 2016; 4: 52. [Ruzhenkov V.A., Shulichenko E.A. Mental dysfunction among women with symptomatic benign dys-plasia of the breast. Modern Problems of Science and Education. 2016; (4): 52. (in Russian)].
- Керчелаева С.Б., Сметник А.А., Беспалов В.Г. Мастопатия и профилактика рака молочной железы как междисциплинарная проблема. РМЖ. Мать и дитя. 2016; 24(15): 1018-25. [Kerchelaeva S.B., Smetnik A.A., Bespalov V.G. Mastopathy and breast cancer prevention as interdisciplinary problem. RMJ. 2016; 24(15): 1018-25. (in Russian)].
- Кравченко Е.Н., Ожерельева М.А. Cостояние молочных желез при гинекологических заболеваниях (литературный обзор). Мать и дитя в Кузбассе. 2014; 2: 19-23. [Kravchenko E.N., Ozhereleva M.A. State of breast to the gynecological disease. Mother and Child in Kuzbass. 2014; (2): 19-23. (in Russian)].
- Сутурина Л.В. Cовременные подходы к оценке рисков и профилактике заболеваний молочной железы. Женское здоровье и репродукция. 2019; 9(-10: 3-15. [Suturina L.V. Modern approaches to risk assessment and prevention of breast diseases. Women's Health and Reproduction. 2019; 9-10: 3-15. (in Russian)].
- Киселев В.И., Сметник В.П., Сутурина Л.В., Селиванов С.П., Рудакова Е.Б., Рахматуллина И.Р., Андреева Е.Н., Фадеева Н.И., Хасанов Р.Ш., Кулагина Н.В., Рожкова Н.И., Артымук Н.В., Гависова А.А.,Муйжнек Е.Л., Кузнецов И.Н., Друх В.М. Индолкарбинол – метод мультитаргетной терапии при циклической мастодинии. Акушерство и гинекология. 2013; 7: 56-63. [Kiselev V.I., Smetnik V.P., Suturina L.V., Selivanov S.P., Rudakova E.B., Rakhmatullina I.R., Andreyeva E.N., Fadeyeva N.I., Khasanov R.Sh., Kulagina N.V., Rozhkova N.I., Artymuk N.V., Gavisova A.A., Muizhnek E.L., Kuznetsov I.N., Drukh V.M. Indole carbinol (Indinol Forto) is a multitargeted therapy option for cyclic mastodynia. Obstetrics and Gynecology. 2013; (7): 56-63. (in Russian)].
- Сметник В.П., Гависова А.А., Билак Н.П., Друх В.М. Эффективность индолкарбинола при циклической мастодинии. Проблемы репродукции. 2013; 5: 49-53. [Smetnik V.P., Gavisova A.A., Bilak N.P., Drukh V.M. Indolecarbinol efficacy for mastalgia treatment. Russian Journal of Human Reproduction. 2013; (5): 4953. (in Russian)].
- Леваков С.А., Кавиладзе М.Г., Гелашвили А.З. Эффективность применения препарата индинол форто у пациенток с дисгормональными заболеваниями молочных желез. Фармакология & Фармакотерапия. 2022; 1: 90-4. [Levakov S.A., Kaviladze M.G., Gelashvili A.Z. The effectiveness of the drug Indinol forto in patients with dyshormonal diseases of the mammary glands. Pharmacology & Pharmacotherapy. 2022; (1): 90-4. (in Russian)].https://dx.doi.org/10.46393/27132129_2022_1_90.
- Хияева В.А. Опыт применения индолкарбинола при мастопатиях. Медицинский совет. 2019; 13: 154-8. [Khiyaeva V.A. Experience with indolecarbinol used to treat mastopathy. Medical Council. 2019; (13): 154-8. (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2019-13-154-158.
- Тазина Т.В. Патогенетически обоснованная терапия циклической масталгии. Акушерство и гинекология. 2020; 9: 187-90. [Tazina T.V. Pathogenetically based therapy for cyclic mastalgia. Obstetrics and Gynecology. 2020; (9): 187-90. (in Russian)]. https://dx.doi.org/10.18565/aig.2020.9.187-190.
- Тазина Т.В. Современный подход к терапии циклической масталгии у коморбидных пациенток. Акушерство и гинекология. 2021; 5: 158-64. [Tazina T.V. A modern approach to therapy for cyclic mastalgia in comorbid patients. Obstetrics and Gynecology. 2021; (5): 158-64. (in Russian)].https://dx.doi.org/10.18565/aig.2021.5.158-164.
- Боровиков И.О., Куценко И.И., Булгакова В.П., Боровикова О.И. Негормональная терапия пациенток с фиброзно-кистозной мастопатией в сочетании с гиперплазией эндометрия. Медицинский совет. 2021; 21-1: 182-9. [Borovikov I.O., Kutsenko I.I., Bulgakova V.P.,Borovikova O.I. Non-hormonal therapy of patients with fibrocystic mastopathy in combination with endometrial hyperplasia. Medical Council. 2021; (21-1): 182-9. (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2021-21-1-182-189.
Received 31.01.2023
Accepted 06.02.2023
About the Authors
Elena N. Kravchenko, Dr. Med. Sci., Professor, Professor at the Department of Obstetrics and Gynecology No. 1, Omsk State Medical University, Ministry of Health of Russia, +7(3812)23-02-93, +7(913)620-81-62, kravchenko.en@mail.ru, 644043, Russia, Omsk, Lenin str., 12.Maxim V. Naboka, Assistant, Department of Oncology, Radiation Therapy, Omsk State Medical University, Ministry of Health of Russia, +7(3812)60-17-46, +7(913)976-16-64, nabokamax@mail.ru, 644099, Russia, Omsk, Lenin str., 12.
Similar Articles
